WO2010047296A1 - 新規ピリミジン誘導体およびHMG-CoA還元酵素阻害剤中間体の製造方法 - Google Patents
新規ピリミジン誘導体およびHMG-CoA還元酵素阻害剤中間体の製造方法 Download PDFInfo
- Publication number
- WO2010047296A1 WO2010047296A1 PCT/JP2009/067987 JP2009067987W WO2010047296A1 WO 2010047296 A1 WO2010047296 A1 WO 2010047296A1 JP 2009067987 W JP2009067987 W JP 2009067987W WO 2010047296 A1 WO2010047296 A1 WO 2010047296A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- carbon atoms
- formula
- methyl
- following formula
- Prior art date
Links
- 0 CC(C)c1c(C*)c(-c(cc2)ccc2F)nc(N(C)S(C)(=O)=O)n1 Chemical compound CC(C)c1c(C*)c(-c(cc2)ccc2F)nc(N(C)S(C)(=O)=O)n1 0.000 description 2
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
Definitions
- the present invention relates to a method for producing a novel pyrimidine derivative and an HMG-CoA reductase inhibitor intermediate.
- the present invention has the following formula (1):
- R 1 represents an optionally substituted alkyl group having 1 to 18 carbon atoms, an aryl group having 6 to 18 carbon atoms, and an aralkyl group having 7 to 18 carbon atoms).
- the present invention also includes a phosphonate represented by the above formula (3) and the following formula (4):
- R 2 represents an optionally substituted alkyl group having 1 to 18 carbon atoms, an aryl group having 6 to 18 carbon atoms, or an aralkyl group having 7 to 18 carbon atoms.
- R 2 is the same as defined above, and relates to a method for producing an intermediate of an HMG-CoA reductase inhibitor.
- R 1 represents an optionally substituted alkyl group having 1 to 12 carbon atoms, an aryl group having 6 to 18 carbon atoms, and an aralkyl group having 7 to 18 carbon atoms
- R 1 represents an optionally substituted alkyl group having 1 to 12 carbon atoms, an aryl group having 6 to 18 carbon atoms, and an aralkyl group having 7 to 18 carbon atoms
- tert-butyl (E)-( which is an important intermediate of a novel pyrimidine derivative and an HMG-CoA reductase inhibitor, in an industrially advantageous form using an inexpensive reagent.
- FIG. 2 is an X-ray powder analysis spectrum for a typical sample of dimethyl [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-ylmethyl] phosphonate.
- the vertical axis represents the X-ray intensity (cps), and the horizontal axis represents the diffraction angle (2 ⁇ ).
- X represents a leaving group
- examples of X include halogen atoms such as iodine atom, bromine atom and chlorine atom, and sulfonate esters such as methanesulfonate, p-toluenesulfonate and trifluoromethanesulfonate. it can.
- Substitution from a hydroxyl group to a halogen atom includes a method using thionyl chloride (substitution to chlorine atom), a method using phosphorus tribromide (conversion to bromine atom), a method using iodine and triphenylphosphine (conversion to iodine atom)
- a method of substituting a hydroxyl group with a halogen atom may be applied.
- the conversion into a sulfonic acid ester can be usually performed by a method of synthesizing a sulfonic acid ester, that is, a method of allowing a sulfonic acid halide or a sulfonic acid anhydride to act in the presence of a base.
- a method of synthesizing a sulfonic acid ester that is, a method of allowing a sulfonic acid halide or a sulfonic acid anhydride to act in the presence of a base.
- 5-bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidine can be produced by the method of Reference Example 1.
- the phosphonic acid ester represented by this is produced.
- R 1 represents an optionally substituted alkyl group having 1 to 18 carbon atoms, an aryl group having 6 to 18 carbon atoms, or an aralkyl group having 7 to 18 carbon atoms.
- substituents include, but are not limited to, an alkyl group, a halogen atom, a trialkylsilyl group, a triarylsilyl group, an alkylarylsilyl group, and an alkoxy group.
- Examples of the optionally substituted alkyl group having 1 to 18 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl
- Examples thereof include a group, neopentyl group, hexyl group, octyl group, nonyl group, decyl group, undecyl group, dodecyl group, tridecyl group, tetradecyl group, pentadecyl group, hexadecyl group, heptadecyl group and octadecyl group.
- Examples of the optionally substituted aryl group having 6 to 18 carbon atoms include a phenyl group, a p-methoxyphenyl group, a p-chlorophenyl group, and a naphthyl group.
- Examples of the optionally substituted aralkyl group having 7 to 18 carbon atoms include benzyl group, p-methoxybenzyl group, naphthylmethyl group and the like.
- the phosphite used is preferably trimethyl phosphite or triethyl phosphite, more preferably trimethyl phosphite.
- the amount of the phosphite ester is not particularly limited, but is usually in the range of 1 to 10 times molar equivalent based on the molar equivalent of the compound represented by the formula (1), preferably The molar equivalent is 1 to 5 times, more preferably 1 to 3 times molar equivalent.
- the molar equivalent is 1 to 5 times, more preferably 1 to 3 times molar equivalent.
- This reaction can be performed under solvent-free conditions or in the presence of a solvent.
- the solvent to be used is not particularly limited, but aliphatic hydrocarbons such as n-hexane, n-pentane, cyclohexane and methylcyclohexane, aromatic hydrocarbons such as toluene, ethylbenzene and o-dichlorobenzene, acetic acid Acetic esters such as methyl, ethyl acetate, isopropyl acetate and n-butyl acetate, nitriles such as acetonitrile and propionitrile, amides such as N, N-dimethylformamide and N, N-dimethylacetamide, diethyl ether, tert -Ethers such as butyl methyl ether and tetrahydrofuran can be exemplified.
- aromatic hydrocarbons are preferred, and toluene is particularly preferred.
- these solvents may be used alone, or two or more kinds of solvents may be mixed and
- the amount of the solvent to be used is not particularly limited, but is usually 1 to 50 times by volume, preferably 1 to 20 times by volume, based on the weight of the compound represented by the formula (1).
- the volume is preferably 1 to 10 times.
- the reaction temperature is not particularly limited, but is usually in the range of 0 ° C. to 250 ° C., preferably 25 ° C. to 200 ° C., more preferably 50 ° C. to 200 ° C.
- the reaction time is not particularly limited, but is usually within a range of 1 to 100 hours, preferably 1 to 72 hours, and more preferably 1 to 48 hours.
- This reaction can also be carried out in an air atmosphere, but is preferably carried out in an inert gas atmosphere.
- an inert gas atmosphere For example, helium, nitrogen, argon and the like are preferable, and nitrogen and argon are more preferable.
- the method of the present invention is represented by the above formula (3), which is the target product directly from the reaction solution, without performing a purification operation such as a silica gel column, which is difficult to implement industrially from an equipment or economic viewpoint.
- the compound can be isolated and purified as crystals continuously following the reaction. That is, the reaction solvent can be used as it is as the crystallization solvent.
- an organic solvent of a type different from the reaction solvent may be added.
- the type of solvent to be added is not particularly limited, but aliphatic hydrocarbons such as n-hexane, n-pentane, cyclohexane and methylcyclohexane are preferable, and hexane is more preferable.
- a different solvent may be added to the reaction mixture for crystallization.
- a technique usually used for crystallization may be applied as appropriate, and is not particularly limited.
- the reaction mixture solution is heated and then cooled. Cooling crystallization method to crystallize by adding seed crystals to the reaction mixture to promote crystallization, Concentrating crystallization method to crystallize after concentrating the reaction mixture solution to an appropriate concentration to make a supersaturated solution
- the method of adding a poor solvent to lower the solubility and crystallizing may be used alone or in appropriate combination.
- the temperature at the time of crystallization is not particularly limited, but is usually in the range of ⁇ 50 ° C. to 50 ° C., preferably in the range of ⁇ 25 to 30 ° C., more preferably ⁇ 15 ° C. to 15 ° C. Is within the range.
- Crystallization can be carried out in an air atmosphere, but can also be carried out in an inert gas atmosphere following the reaction.
- the inert gas in that case can illustrate the same gas as the said reaction conditions.
- the crystallization mother liquor contains an excessively used phosphite, so this mother liquor can also be used directly in the next reaction.
- boiling point of the phosphite ester is low (boiling point 111 to 112 ° C.), such as trimethyl phosphite, it can be reused after separation from the reaction mixture by concentration.
- the by-product compound corresponding to R 1 -X also has a low-boiling halogenation. It becomes alkyl and can be easily separated and recovered from the reaction mixture.
- the method for producing a phosphonate represented by the formula (3) according to the present invention merely provides a novel pyrimidine derivative and a method for producing an HMG-CoA reductase inhibitor using the same. In addition, it is an excellent production method from an industrial viewpoint and an environmental load viewpoint.
- a method for producing an HMG-CoA reductase inhibitor intermediate represented by the formula The compound represented by the formula (3) may be obtained by the above method or may be obtained by other methods.
- R 2 represents an optionally substituted alkyl group having 1 to 18 carbon atoms, an aryl group having 6 to 18 carbon atoms, or an aralkyl group having 7 to 18 carbon atoms.
- substituents include the same as those for R 1 .
- Examples of the optionally substituted alkyl group having 1 to 18 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl
- Examples thereof include a group, a neopentyl group, a hexyl group, an octyl group, a nonyl group, a decyl group, an undecyl group, a dodecyl group, a tridecyl group, a tetradecyl group, a pentadecyl group, a hexadecyl group, a heptadecyl group, and an octadecyl group.
- Examples of the optionally substituted aryl group having 6 to 18 carbon atoms include a phenyl group, a p-methoxyphenyl group, a p-chlorophenyl group, and a naphthyl group.
- Examples of the optionally substituted aralkyl group having 7 to 18 carbon atoms include benzyl group, p-methoxybenzyl group, naphthylmethyl group and the like.
- tert-butyl is preferred as R 2 .
- the amount of the compound represented by the formula (4) is not particularly limited, but is usually 0.8 to 2. with respect to the molar equivalent of the phosphonic acid ester represented by the formula (3). It is in the range of 0 equivalents, preferably in the range of 1.0 to 1.5 equivalents.
- the compound represented by the above formula (4) is, for example, tert-butyl 2-[(4R, 6S) described in Japanese Patent No. 2573919, Tetrahedron-Letters, Vol. 31, pages 2545-2548, 1990. ) -6-Hydroxymethyl-2,2-dimethyl-1,3-dioxane-4-yl) acetate is allowed to react with dimethyl sulfoxide, triethylamine, oxalyl chloride (Swan oxidation method), or described in Reference Example 2 It can manufacture with the manufacturing method of.
- the kind of base is not particularly limited, and an inorganic base or an organic base can be used.
- the inorganic base include alkali metal hydroxides such as lithium hydroxide, sodium hydroxide and cesium hydroxide, alkaline earth metal hydroxides such as magnesium hydroxide, calcium hydroxide and strontium hydroxide, and lithium hydride.
- metal hydrides such as sodium hydride and calcium hydride.
- organic base examples include lithium diisopropylamide, lithium-2,2,6,6-tetramethylpiperazide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, and potassium hexamethyldisilazide.
- Amide type base Grignard reagent such as isopropylmagnesium bromide, tert-butylmagnesium chloride, 1,8-diazabicyclo [4.5.0] -7-undecene, 1,4-diazabicyclo [2.2.2] octane, etc.
- organic amine bases examples include lithium diisopropylamide, lithium-2,2,6,6-tetramethylpiperazide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, and potassium hexamethyldisilazide.
- Amide type base Grignard reagent such as isopropylmagnesium bromide, tert-but
- amide type bases of lithium diisopropylamide, lithium-2,2,6,6-tetramethylpiperazide, lithium hexamethyldisilazide, sodium hexamethyldisilazide and potassium hexamethyldisilazide are preferable, and more preferable.
- This reaction is usually carried out in an inert gas atmosphere.
- an inert gas atmosphere for example, helium, nitrogen, neon, argon and the like can be exemplified, and among these, nitrogen and argon are preferable.
- the amount of the base used is not particularly limited, but is usually within the range of 0.8 to 2.0 equivalents relative to the molar equivalent of the phosphonic acid ester represented by the formula (3), preferably Is in the range of 1.0 to 1.5 equivalents, more preferably in the range of 1.0 to 1.3 equivalents.
- This reaction is usually carried out in the presence of a solvent. Since the reaction is carried out in the presence of a base, it is necessary to select a solvent that does not react with the base. However, such a solvent is not particularly limited. Moreover, a solvent may be used independently or may mix and use two or more types of solvents in arbitrary ratios.
- aliphatic hydrocarbons such as n-hexane, n-pentane, cyclohexane and methylcyclohexane
- aromatic hydrocarbons such as toluene, ethylbenzene and o-dichlorobenzene, diethyl ether, tert-butyl methyl ether, tetrahydrofuran and the like
- Ethers can be exemplified.
- aromatic hydrocarbons and ethers are preferable, and toluene and tetrahydrofuran are particularly preferable.
- the amount of the solvent used is not particularly limited, but is usually within a range of 1 to 100 times volume, preferably 5 to 60 times the dose of the phosphonate represented by the formula (3) to be used. And more preferably within the range of 5 to 50 times the capacity.
- the reaction temperature is not particularly limited as long as it is not higher than the boiling point of the solvent used normally, but is preferably in the range of ⁇ 100 ° C. to 100 ° C., more preferably ⁇ 100 ° C. to 30 ° C. Preferably, it is within the range of ⁇ 100 ° C. to 20 ° C.
- the HMG-CoA reductase inhibitor intermediate represented by the above formula (5) synthesized in this way can be easily isolated from the reaction mixture by a commonly used operation such as extraction, Further, it can be isolated directly from the reaction mixture by crystallization operation, and its purity can be increased.
- R 1 may be substituted, an alkyl group having 1 to 18 carbon atoms, an aryl group having 6 to 18 carbon atoms, or a carbon number.
- Pyrimidine derivatives having 7 to 18 aralkyl groups are novel compounds that are unknown in the literature.
- pyrimidine derivatives (dimethyl [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-ylmethyl] phosphonate) wherein R 1 is a methyl group are HMG-CoA It is an effective compound for the synthesis of reductase inhibitor intermediates.
- 2 ⁇ is about 9.8 o , 17.4 o , 18.0 o , 18.8 o , 20.5 o , 20.9 o , 22.1 o , 23.9 o , 24.7 o , and 29.6 o have 10 most prominent peaks in XRD.
- the X-ray powder analysis spectrum was measured by uniformly filling a crystalline sample into a concave portion of a slide glass having a concave surface. The sample was scanned in the range of 2.000 to 60.000 o at a scan speed of 2.000 o / min.
- the X-ray source CuK ⁇ 1 line was used, and measurement was performed at a tube voltage of 30 kV and a tube current of 15 mA.
- FIG. 1 shows an X-ray powder analysis spectrum for the above pyrimidine derivative sample.
- the 2 ⁇ value of the X-ray powder analysis pattern may vary slightly from instrument to instrument or from sample to sample, so the values in the drawing should not be interpreted as absolute values.
- the X-ray powder analysis pattern is important in terms of data properties when determining the identity of the crystal.
- reaction solution was stirred at 0 ° C. for 1 hour, and then the aqueous layer was separated.
- the organic layer was further diluted with ethyl acetate (100 ml), washed successively with 5% aqueous sodium thiosulfate solution (75 ml) and water (40 ml ⁇ 2), and then dried over anhydrous magnesium sulfate.
- the organic solvent was evaporated under reduced pressure, methanol (40 ml) was added, and the mixture was heated to 55 ° C. After cooling the solution to 45 ° C., crystals of the title compound prepared in advance were added as seed crystals (about 10 mg). After confirming crystallization, the solution was cooled to room temperature. The mixture was further cooled to ⁇ 10 ° C. and aged for 30 minutes. The precipitated crystals were collected by filtration, and the cake was washed with methanol ( ⁇ 10 ° C., 15 ml). Drying under reduced pressure at 40 ° C. gave 3.9 g of the title compound.
- Example 4 The X-ray powder analysis spectrum for dimethyl [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-ylmethyl] phosphonate prepared in Example 1 is shown in FIG. .
- 2 ⁇ is about 9.8 °, 17.4 o , 18.0 o , 18.8 o , 20.5 o , 20.9 o , 22.1 o , 23.9 o , 24.7 o , and 29
- X-ray powder crystal analyzer MiniFlex-II manufactured by Rigaku Corporation Measurement conditions: CuK ⁇ 1- wire tube voltage 30 kV Current between 15 mA
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
1H-NMR(CDCl3):δ1.36(6H,d,J=6.6Hz)、3.48(1H,m)、3.51(3H,s)、3.56(3H,s)、4.48(2H,s)、7.20(2H,m)、7.80(2H,m)。
1H-NMR(CDCl3):δ1.35(1H,q,J=12.7Hz)、1.45(9H,s)、1.46(3H,s)、1.49(3H,s)、1.83(1H,dt,J=2.7Hz,12.9Hz)、2.35(1H,dd,J=5.9Hz,15.4Hz)、2.46(1H,dd,J=7.1Hz、15.4Hz)、4.33(1H,m)、9.58(1H,s)。
1H-NMR(CDCl3):δ1.30(6H,d,J=6.6Hz)、3.30(2H,d,J=22.0Hz)、3.44(1H,quint,J=6.6Hz)、3.49(3H,s)、3.54(3H,s)、3.55(3H,s)、3.58(3H,s)、7.17(2H,m)、7.59(2H,m)。
1H-NMR(CDCl3):δ1.13(1H,q,J=12.7Hz)、1.26(3H,d,J=6.8Hz)、1.27(3H,d,J=6.8Hz)、1.40(3H,s)、1.46(9H,s)、1.49(3H,s)、1.54(1H,dt,J=2.5Hz,12.7Hz)、2.30(1H,dd,J=6.3Hz,15.4Hz)、2.45(1H,dd,J=6.8Hz,15.4Hz)、3.38(1H,sep,J=6.8Hz)、3.52(3H,s)、3.57(3H,s)、4.28(1H,m)、4.43(1H,m)、5.46(1H,dd,J=5.4Hz,16.4Hz)、6.51(1H,dd,J=1.2Hz,16.4Hz)、7.08(2H,m)、7.64(2H,m)。
実施例1にて製造したジメチル[4-(4-フルオロフェニル)-6-イソプロピル-2-[メチル(メチルスルホニル)アミノ]ピリミジン-5-イルメチル]ホスホネートに対するX線粉末解析スペクトルを図1に示す。2θが約9.8°、17.4o、18.0o、18.8o、20.5o、20.9o、22.1o、23.9o、24.7o、および29.6oにおいて、XRD中に10個の最も顕著なピークが見られる。
X線粉末結晶解析装置 : 株式会社リガク製 MiniFlex-II
測定条件 : CuKα1線
管電圧30kV
間電流15mA
Claims (8)
- 前記式(3)で表されるホスホン酸エステルが、請求項1に記載の方法によって製造されたものである、請求項2に記載の製造方法。
- Xが塩素原子、臭素原子、またはヨウ素原子である、請求項1~3のいずれかに記載の製造方法。
- R1がメチル基であり、R2がtert-ブチル基である、請求項1~4のいずれかに記載の製造方法。
- R1がメチル基である、請求項6に記載のピリミジン誘導体。
- 2θ=9.8o、17.4o、18.0o、18.8o、20.5o、20.9o、22.1o、23.9o、24.7o、および29.6oにおいて特異的ピークを示すX線粉末解析パターンを有する、請求項7に記載のピリミジン誘導体。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09821993.4A EP2351762B1 (en) | 2008-10-20 | 2009-10-19 | NOVEL PYRIMIDINE DERIVATIVE AND METHOD FOR PRODUCING HMG-CoA REDUCTASE INHIBITOR INTERMEDIATE |
CN2009801412985A CN102186869A (zh) | 2008-10-20 | 2009-10-19 | 新嘧啶衍生物及HMG-CoA还原酶抑制剂中间体的制造方法 |
JP2010534798A JPWO2010047296A1 (ja) | 2008-10-20 | 2009-10-19 | 新規ピリミジン誘導体およびHMG−CoA還元酵素阻害剤中間体の製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008270076 | 2008-10-20 | ||
JP2008-270076 | 2008-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010047296A1 true WO2010047296A1 (ja) | 2010-04-29 |
Family
ID=42119335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/067987 WO2010047296A1 (ja) | 2008-10-20 | 2009-10-19 | 新規ピリミジン誘導体およびHMG-CoA還元酵素阻害剤中間体の製造方法 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2351762B1 (ja) |
JP (1) | JPWO2010047296A1 (ja) |
CN (1) | CN102186869A (ja) |
WO (1) | WO2010047296A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016501183A (ja) * | 2012-11-12 | 2016-01-18 | ヴィクトリア リンク リミテッドVictoria Link Limited | (3r,4s)−l−((4−アミノ−5h−ピロロ[3,2−d]ピリミジン−7−イル)メチル)−4−(メチルチオメチル)ピロリジン−3−オール(mtdia)の塩及び多形形態 |
US9695130B2 (en) | 2014-02-06 | 2017-07-04 | Api Corporation | Rosuvastatin calcium and process for producing intermediate thereof |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103113356A (zh) * | 2013-03-07 | 2013-05-22 | 上海现代制药股份有限公司 | 一种罗苏伐他汀钙的中间体的制备方法 |
WO2014203045A1 (en) | 2013-06-20 | 2014-12-24 | Lupin Limited | A novel, green and cost effective process for synthesis of tert-butyl (3r,5s)-6-oxo-3,5-dihydroxy-3,5-o-isopropylidene-hexanoate |
JP2017512183A (ja) | 2014-02-13 | 2017-05-18 | リガンド・ファーマシューティカルズ・インコーポレイテッド | プロドラッグ化合物およびそれらの使用 |
US11970482B2 (en) | 2018-01-09 | 2024-04-30 | Ligand Pharmaceuticals Inc. | Acetal compounds and therapeutic uses thereof |
CN115819408A (zh) * | 2022-10-21 | 2023-03-21 | 宿迁阿尔法科技有限公司 | 一种高选择性合成瑞舒伐他汀关键中间体的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2573819B2 (ja) | 1987-12-08 | 1997-01-22 | ヘキスト・アクチェンゲゼルシャフト | アルデヒドおよびその製法 |
WO2000049014A1 (en) | 1999-02-17 | 2000-08-24 | Astrazeneca Ab | Process for the production of tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate |
WO2005054207A1 (en) | 2003-12-04 | 2005-06-16 | Glenmark Pharmaceuticals Limited | Process for the preparation of pyrimidine derivatives |
CN1687087A (zh) | 2005-05-16 | 2005-10-26 | 浙江海正药业股份有限公司 | 瑞舒伐他汀及其中间体的制备方法 |
WO2007017117A1 (en) | 2005-07-28 | 2007-02-15 | Lek Pharmaceuticals D.D. | Process for the synthesis of rosuvastatin calcium |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05310700A (ja) * | 1992-05-12 | 1993-11-22 | Sagami Chem Res Center | 縮合ピリジン系メバロノラクトン中間体及びその製法 |
-
2009
- 2009-10-19 EP EP09821993.4A patent/EP2351762B1/en not_active Not-in-force
- 2009-10-19 WO PCT/JP2009/067987 patent/WO2010047296A1/ja active Application Filing
- 2009-10-19 JP JP2010534798A patent/JPWO2010047296A1/ja active Pending
- 2009-10-19 CN CN2009801412985A patent/CN102186869A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2573819B2 (ja) | 1987-12-08 | 1997-01-22 | ヘキスト・アクチェンゲゼルシャフト | アルデヒドおよびその製法 |
WO2000049014A1 (en) | 1999-02-17 | 2000-08-24 | Astrazeneca Ab | Process for the production of tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate |
JP2003518474A (ja) * | 1999-02-17 | 2003-06-10 | アストラゼネカ アクチボラグ | tert−ブチル(E)−(6−[2−[4−(4−フルオロフェニル)−6−イソプロピル−2−[メチル(メチルスルホニル)アミノ]ピリミジン−5−イル]ビニル](4R,6S)−2,2−ジメチル[1,3]ジオキサン−4−イル)アセテートの製造法 |
WO2005054207A1 (en) | 2003-12-04 | 2005-06-16 | Glenmark Pharmaceuticals Limited | Process for the preparation of pyrimidine derivatives |
CN1687087A (zh) | 2005-05-16 | 2005-10-26 | 浙江海正药业股份有限公司 | 瑞舒伐他汀及其中间体的制备方法 |
WO2007017117A1 (en) | 2005-07-28 | 2007-02-15 | Lek Pharmaceuticals D.D. | Process for the synthesis of rosuvastatin calcium |
Non-Patent Citations (2)
Title |
---|
See also references of EP2351762A4 * |
TETRAHEDRON LETTERS, vol. 31, 1990, pages 2545 - 2548 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016501183A (ja) * | 2012-11-12 | 2016-01-18 | ヴィクトリア リンク リミテッドVictoria Link Limited | (3r,4s)−l−((4−アミノ−5h−ピロロ[3,2−d]ピリミジン−7−イル)メチル)−4−(メチルチオメチル)ピロリジン−3−オール(mtdia)の塩及び多形形態 |
US9695130B2 (en) | 2014-02-06 | 2017-07-04 | Api Corporation | Rosuvastatin calcium and process for producing intermediate thereof |
US10377722B2 (en) | 2014-02-06 | 2019-08-13 | Api Corporation | Rosuvastatin calcium and process for producing intermediate thereof |
Also Published As
Publication number | Publication date |
---|---|
EP2351762B1 (en) | 2013-10-16 |
EP2351762A4 (en) | 2012-07-18 |
EP2351762A1 (en) | 2011-08-03 |
JPWO2010047296A1 (ja) | 2012-03-22 |
CN102186869A (zh) | 2011-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010047296A1 (ja) | 新規ピリミジン誘導体およびHMG-CoA還元酵素阻害剤中間体の製造方法 | |
JP6693859B2 (ja) | プロスタグランジンアミドの新規製造方法 | |
WO2004103977A2 (en) | Process for the preparation of pyrimidine derivatives | |
CN107531680B (zh) | 一种毒素及其中间体的制备方法 | |
KR101728443B1 (ko) | 2-아미노니코틴산벤질에스테르 유도체의 제조 방법 | |
JP4139334B2 (ja) | 新規ボロネートエステル | |
JP5644917B2 (ja) | 3−(4−テトラヒドロピラニル)−3−オキソプロパン酸アルキル化合物及び4−アシルテトラヒドロピランの製法 | |
JP5968900B2 (ja) | ロスバスタチン塩の製法 | |
US4937308A (en) | Preparation of alkyl O,O-dialkyl-γ-phosphonotiglates | |
CN103804414A (zh) | 用于制备瑞舒伐他汀钙的中间体化合物以及由其制备瑞舒伐他汀钙的方法 | |
RU2402564C2 (ru) | Способ получения n-пиразиноил-(l)-фенилаланил-(l)-лейцинбороновой кислоты или ее ангидрида | |
JP2008184419A (ja) | 高純度トリアルキルインジウム及びその製法 | |
JP3619277B2 (ja) | ジヒドロポリプレニルモノホスフェートの製造方法及びその中間体化合物 | |
JP4070608B2 (ja) | 光学的に活性なジヒドロピロンの製造方法 | |
JPS6232188B2 (ja) | ||
JP4561635B2 (ja) | 4−アルコキシカルボニルテトラヒドロピラン又はテトラヒドロピラニル−4−カルボン酸の製法 | |
JP2006512386A (ja) | ホスホロジアミダイト生産方法 | |
JP2005075734A (ja) | 光学活性ホモクエン酸の製法 | |
JP4710698B2 (ja) | シリルエーテル基を有するβ−ジケトン化合物の製造法 | |
US20020165269A1 (en) | Process for preparing optically active dihydropyrones | |
JP2008120759A (ja) | エーテル基を有するβ−ジケトン化合物の製造法 | |
JPH0219832B2 (ja) | ||
EP1398312A1 (en) | Beta-substituted-gamma-butyrolactones and a process for preparation thereof | |
KR20030077183A (ko) | 심바스타틴 및 이의 중간체 화합물들의 개선된 제조방법 | |
KR20030059724A (ko) | 이미다졸 유도체의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980141298.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09821993 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010534798 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1534/KOLNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009821993 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |